U.S. Diabetes Therapies and Complications Markets “The growing demand and the introduction of technologically advanced products is likely to transform this market into a highly lucrative and profitable segment within the pharmaceuticals industry.” Pharmaceuticals Analyst Team Frost & Sullivan

Increase in diagnosed diabetic population inflates market potential. Introduction of technologically superior therapies increases cost of therapy and drives revenues. Entry of more number of players and cross-segment moves intensifies leadership strife. Non-invasive insulin technologies to cause increase in the use of insulin by the diabetics. Launch of diabetes complications products to affect clinical management of diabetes and the market landscape. Industry Trends

Frost & Sullivan provides: Detailed insights into recent developments and trends Drivers, restraints, challenges, and strategic recommendations Analyst insights on ‘hot topics” and emerging applications in the pharmaceuticals market Market sizing and competitive analysis Market forecasts and opportunity analysis Key Features

Coverage: The United States Proven methodology encompassing extensive primary and secondary data and research Focused information and strategies that cover business and technology issues Credible data and analysis highlighting industry dynamics Winning strategies to help you create precise business plans What We Offer

Current Market Participants Find out how you compare to the competition Assess current and future drivers and restraints Determine and exploit new market share opportunities New Entrants Analyze challenges associated with the industry Calculate time scales for strategy implementation Position yourself to capitalize on the market’s unmet needs Investment Community Analyze long-term strategies of pharmaceutical companies Determine which participants will outperform the competition Assess attractiveness of investing in pharmaceutical market Who Will Benefit?

Insulin Therapies Oral Diabetes Medications -Sulfonylureas -Biguanides -Alpha-Glucosidase Inhibitors (AGIs) -Glitazones -Meglitinides.Diabetes Complications Products -Diabetic Nephropathy -Diabetic Neuropathy -Diabetic Retinopathy What’s Included

Aerogen, Inc. Alizyme Plc. Alkermes, Inc. Allergan, Inc. Alteon, Inc. Amylin Pharmaceuticals, Inc. Anergen, Inc. Aradigm Corp. Astra Zeneca Pharmaceuticals LP Aurogen, Inc. Autoimmune, Inc. Aventis Pharmaceuticals, Inc. Battelle Medical Products Bayer Corp. Biobras S.A. BioSante Pharmaceuticals, Inc. Biostratum, Inc. Bristol-Myers Squibb Co. Calyx Therapeutics, Inc. Cangene Corp. ConjuChem, Inc. CP Pharmaceuticals Ltd Dainippon Pharmaceutical Co., Ltd. Diamyd Medical AB Diosynth BV Dongbao Pharmaceuticals Ltd. Eli Lilly and Co. EMD Pharmaceuticals Emisphere Technologies, Inc. Epicept Corp. Ergo Science Corp. Exocell, Inc. Flamel Technologies Fujisawa Healthcare, Inc. Generex Biotechnology Corp. Genpharm, Inc. GlaxoSmithkline Hoffmann-La Roche, Inc. Inhale Therapeutic Systems, Inc. Key Market Participants

Insmed, Inc. Isis Pharmaceuticals, Inc. Johnson & Johnson Pharmaceutical Research & Development Karo Bio AB Keryx Biopharmaceuticals, Inc. Ligand Pharmaceuticals, Inc. Maxia Pharmaceuticals, Inc. Merck & Co., Inc. Metabolex, Inc. Neurocrine Biosciences, Inc. Nexell Therapeutics, Inc. Nobex Corp. Novartis Pharmaceuticals Corp. Novo Nordisk Pharmaceuticals, Inc Organogenesis Inc. Pfizer, Inc. Pharmacia Corp. Reddy US Therapeutics, Inc. Sankyo Pharma, Inc. Scios, Inc. Servier International Takeda Pharmaceuticals North America, Inc. The Institute of Diabetes Discovery The Quigley Corp. Watson Laboratories, Inc. Wyeth Pharmaceuticals Yamanouchi Pharma America, Inc. Key Market Participants

Call toll free 877 G O F ROST ( ) Fax toll free Visit For More Information